ДЕЛЬМАР Поль (CH),ФЁРНЦЛЕР Дороте (CH),ШЕРЕР Стефан (US)
申请号：
RU2012133472/15
公开号：
RU2012133472A
申请日:
2011.01.18
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of increasing survival without disease progression in a patient suffering from gastrointestinal cancer by adding bevacizumab to a chemotherapy regimen, wherein said method includes: (a) obtaining tissue samples from said patient； (b) determining the expression level of one or more from VEGFA, HER2 and neuropilin； and (c) administering bevacizumab in combination with a chemotherapy regimen to a patient having an increased level of VEGFA and / or a decreased level of HER2 and / or neuropilin relative to the control levels determined in patients diagnosed with metastatic colorectal cancer. 2. An in vitro method for identifying a patient that is responsive or sensitive to the addition of bevacizumab for treatment to a chemotherapy regimen, wherein said method comprises: (a) obtaining tissue samples from a patient suspected of suffering or predisposed to cancer of the gastrointestinal tract； and (b) determining the expression level of one or more of VEGFA, HER2 and neuropilin； where an increased level of VEGFA and / or CD31, and / or a decreased level of HER2 and / or neuropilin relative to the control levels determined in patients suffering from metastatic colorectal and direct cancer intestines, indicates the sensitivity of patients to the addition of bevacizumab to the indicated scheme. 3. The method of claim 1 or 2, wherein the expression level of the VEGFA protein is determined. The method according to any one of claims 1 or 2, wherein the expression level of the HER2.5 protein is determined. The method according to any one of claims 1 to 2, wherein the level of expression of the neuropilin protein is determined. The method of claim 3, wherein said protein expression level is determined using an immunohistochemical method (IHC). The method according to any one of claims 1 or 2, where1. Способ повышения выживаемости без прогрессирования заболевания у пациента, страдающего раком желудочно-кишечного тракта, с помощью добавления бевацизумаба к схеме химиотер
